IBI-110
Advanced Cancers
Phase 2Active
Key Facts
About Innovent Biologics
Innovent Biologics' mission is to develop and commercialize high-quality, innovative medicines that are affordable and accessible to patients worldwide. Its key achievements include a successful 2018 Hong Kong IPO, the commercialization of multiple blockbuster products like Tyvyt® (sintilimab), and the establishment of a deep, diversified pipeline through internal R&D and strategic partnerships. The company's strategy hinges on full integration, global expansion, and leveraging its robust technology platforms to deliver a sustainable portfolio of novel biologics.
View full company profileTherapeutic Areas
Other Advanced Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| DC-6001 (DCBY02) | DynamiCure | Phase 1 |
| DC-6001 (DCSZ11) | DynamiCure | Phase 1 (Planned) |
| INA03 | Inatherys | Preclinical |
| MDX2004 | Opko Health | Phase 1 |
| NXP900 | Nuvectis Pharma | Phase 1 |